MariMed’s Branded Cannabis Products Now Licensed & Distributed in Maryland Dispensaries

NEWTON, Mass. and HAGERSTOWN, Md., May 01, 2018 -- MariMed Inc. (OTCQB:MRMD) has expanded the licensing and distribution of its branded cannabis product line into Maryland. These products are being produced by Kind Therapeutics USA (“Kind”) at its 100,000 sq. ft. state licensed medical marijuana production facility in Hagerstown, Maryland. Kind Therapeutics USA is distributing these products to approximately 35 dispensaries throughout Maryland.

MariMed’s branded cannabis products, including their new Nature’s Heritage Cannabis and Kalm Fusion brands, are now produced and distributed via Kind Therapeutics USA to Maryland dispensaries. Kind Therapeutics USA

MariMed developed the cultivation and production facility and leases it to Maryland cannabis licensee Kind Therapeutics USA.  MariMed provides managed services to Kind and has licensed Kind to produce and distribute the following products:

• The new Nature’s Heritage Cannabis^® strains that MariMed has collected from the finest seed lineages in the world and developed into an organic product line that is “The best cannabis Mother Earth has to offer^®”;
• Kalm Fusion^® precision dosed chewable tablets, powdered tincture drink mix, and oral thin strips in THC and CBD formulations;
• Tikun Olam™ clinically proven effective cannabis strains, flower, oils, salves, lotions, and vape cartridges; and
• LucidMood “sippers” disposable vape pens.

Under MariMed management, the facility has 11 grow rooms currently producing world-class marijuana strains.  Two harvests have been completed, with all organically grown flowers, oil extracts and infused products passing the rigorous purity tests by independent licensed testing labs. 

“This next-gen facility utilizes advanced ecofriendly, sustainable cultivation techniques to produce pesticide and contaminant-free medical marijuana that has the power to transform human health and wellness,” noted Timothy Shaw, MariMed COO and cultivation expert who designed the facility, supervised the build-out and oversees the cultivation team.  “We’ve had robust harvests and are thrilled with the results. As we analyze the data on the first several crops, we look forward to sharing results of our new cultivation techniques for growing the most important medicinal plant on Earth.” 

Shaw added, “In the coming months, we’ll be introducing Tikun Olam world renowned strains from Israel to complement our new Nature’s Heritage branded line of cannabis strains and precision dosed products.”

“We are proud to provide safe, affordable, legal wholesale access to the purest, most consistent medical cannabis possible,” stated Robert Fireman, MariMed CEO. “As more dispensaries open, we expect this facility to provide medical cannabis products to approximately 100 dispensaries throughout Maryland to relieve patients’ symptoms and help them feel and function better.”

About MariMed Inc.:
MariMed designs, develops, finances, and optimizes the success of medical cannabis cultivation, production, and dispensary facilities through its validated management. MariMed's team has developed or is in the process of developing state-of-the art regulatory-compliant facilities in DE, IL, NV, MD, MA and RI. These facilities are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. In addition, MariMed is on the forefront of precision dosed branded products for the treatment of specific medical symptoms. MariMed currently distributes its branded products in select states and is expanding licensing and distribution to numerous additional states encompassing thousands of dispensaries.

MariMed Inc. is one of the 17 top-performing public cannabis companies in the U.S. tracked on the U.S. Marijuana Index, (www.marijuanaindex.com). For additional information, visit www.MariMedAdvisors.com

About Kind Therapeutics USA:
KIND is committed to providing safe, dignified, and affordable wholesale access to medical cannabis for dispensaries across Maryland.
kindtherapeuticsusa.com/

MariMed Contacts:
Business Development
Jon Levine, CFO, MariMed, Inc.
+1 844-244-0200

Investor Relations
Tyler Troup, Circadian Group
[email protected]
+1 (866) 950 8300

Media Relations
Julie Shepherd, Accentuate PR
[email protected]
+1 847-275-3643

Forward Looking Statements:
This release contains certain forward-looking statements and information relating to MariMed Inc., that is based on the beliefs of MariMed Inc. management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the economic environment and changes in the legal status of cannabis. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "planned," "estimated," "preparing," “seek,” "potential," "expected" or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites of any other party referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.

A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/c3dc5b28-465f-4e03-beb1-5ea0b4a172d7